
Education and Training
College/University
University of Delaware
Medical School
Sidney Kimmel Medical College - Thomas Jefferson University
Residency
University of Maryland
Career and Research Goals
My career focus is in the treatment of women with aggressive sub-types of breast cancer such as basal-like (triple negative) and ERBB-2 amplified. My current research goals are finding therapeutic strategies to target the ERBB family of receptors specifically EGFR and ERBB3 in basal-like breast cancer. I hope to characterize the role somatic ERBB3 mutations in primary and metastatic basal type breast cancer. I also have a special interest in early phase drug development and toxicity management.
Honors, awards and distinctions
Alpha Omega Alpha Honor Society
Education and Training
- Hematology-Oncology Fellowship, Duke University School of Medicine, 2015 - 2018
- Internal Medicine Residency, University of Maryland School of Medicine, 2012 - 2015
- M.D., Thomas Jefferson University, Sidney Kimmel Medical College, 2012
Grants
- Multicenter Open Label Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients with Brain Metastasis due to HR+/Her2- Breast Cancer
- A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Meta
- A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2-Locally Advanced or Metastatic Breast Cancer
- Sermonix SMX 18-001
- Evaluation of the effects of endocrine therapy and abemaciclib on host and tumor immune cell repertoire/function in advanced ER+/HER2- breast cancer
- A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab VersusPlacebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients WithHigh-risk, Estrogen Receptor-Positive (ER+), Human Epider
- Phase II Multicenter Study of Durvalumab (MEDI4736) and Olaparib in PlatinumTreated Advanced Triple Negative Breast Cancer ¿ DORA
- Targeting tumor-specific apoptosis regulation in advanced ER+ breast cancer
- Cancer cell intrinsic and extrinsic actions of steroid hormones in breast tumors